NES ZIONA, Israel, August 31, 2015 /PRNewswire/ —
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for vaccines and immunotherapies, announced today it will be delivering two oral presentations on the company’s intradermal delivery device MicronJet™ at the Skin Vaccination Summit in Lausanne, Switzerland on September 2-4.
NanoPass’s Chief Executive Officer, Yotam Levin, MD, will present 8 years of accumulated clinical data while the Company’s Medical Director, Efrat Kochba, MD, will present the results of a recent intradermal iPV (inactivated polio vaccine) in HIV+ subjects.
The oral presentation, titled “Intradermal vaccination using the novel microneedle device MicronJet™: Past, present and future” and the presentation, titled, “NanoPass’ clinical experience with global health vaccines”, will both be held on September 3, 2015 at 17:20 PM and 10:40 AM, respectively.
About NanoPass Technologies Ltd.
NanoPass is a pioneer in the development and commercialization of intradermal (skin) delivery solutions. The company collaborates with a variety of vaccine and immunotherapy product developers. NanoPass and its partners have concluded multiple clinical studies in various fields including vaccines (seasonal, and pandemic influenza, polio and others), cancer and diabetes immunotherapy, insulin delivery and allergy. NanoPass is backed by prominent investors including IHCV, XT Investments, DPartners and Elcam Medical.
MicronJet600™ is a microneedle-based device for intradermal delivery of vaccines and drugs, enabling consistent, nearly painless and simple delivery of therapeutics directly into the skin. MicronJet™ has proven efficacy and safety in multiple applications including flu and other vaccines and is utilized in large international clinical studies.
MicronJet™ is registered for marketing in various territories including the USA, for use by health care professionals for intradermal delivery (see label).
1. Van Damme P et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 2009;27(3):454-9.
2. Hung IFN et.al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012; 30(45):6427-35.
3. Troy SB et al. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. JID Advance Access published January 28, 2015